Matthew Davids, MD, MMSc, from the Dana-Farber Cancer Institute, Boston, MA, discusses the importance of keeping patients with chronic lymphocytic leukemia (CLL) informed of when their Richter’s syndrome occurs, which can be predictive of their prognosis. He adds that his team’s goal in research is to develop better therapies for CLL patients with Richter’s syndrome. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.